Keith Gottesdiener, Prime Medicine CEO

Up­dat­ed: Prime Med­i­cine whit­tles down pipeline, signs gene edit­ing deal with Bris­tol My­ers

Prime Med­i­cine is cut­ting its pipeline, but gain­ing a part­ner.

The gene edit­ing com­pa­ny, which once boast­ed a pipeline of 18 pro­grams, is now fo­cus­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA